• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BoneSupport readies $62m IPO

June 14, 2017 By Brad Perriello

BoneSupportBoneSupport said this week that it’s planning to float an initial public offering that would fetch roughly $62 million at the midpoint, not including an over-allotment option.

The Swedish company, which is developing the Cerament G injectable antibiotic-eluting bone graft substitute, said it plans to offer more than 18.5 million shares at $3.13 to $3.59 apiece (SEK 27 to SEK 31) on the NASDAQ Stockholm exchange, for total proceeds of $57.9 million to $66.4 million (SEK 500 million to SEK 574 million).

The proposed offering, which is set to price June 21, also includes a 2.8-million-share over-allotment worth another $8.7 million (SEK 75 million). Lund, Sweden-based BoneSupport said its investors have already agreed to acquire about $36 million (SEK 236 million) worth of shares in the flotation.

About 25% to 30% of the proceeds are earmarked for a bid for pre-market approval from the FDA for Cerament G, hoped for by 2021, plus clinical studies for its Cerament V product in the U.S. Another 10% is slated for a buildout of BoneSupport’s U.S. sales force, with about 40% planned for other clinical work and adding a pair of products to the pipeline, the company said.

“BoneSupport’s rapid sales growth reflects the clear benefits that our Cerament-based products deliver to patients, surgeons and payers when used to treat bone voids. We believe our IPO will provide us with the funds we need to execute our strategy of driving sales in both the U.S. and Europe, generating additional clinical data to enhance the competitive positioning of our products in trauma and revision arthroplasty and completing the Fortify study, which is a key to gaining U.S. approval for Cerament G,” CEO Richard Davies said in prepared remarks. “Our stronger financial position will also allow us to invest in our pipeline of products that are designed to promote bone growth, an area of significant unmet medical need. We believe that by executing this strategy we can deliver our 2020 financial targets and continue to generate significant value for our shareholders.”

($1 = SEK 8.63993)

Filed Under: Featured, Funding Roundup, Initial Public Offering (IPO), Orthopedics, Wall Street Beat Tagged With: Bonesupport

IN CASE YOU MISSED IT

  • Beta Bionics makes iLet available with Dexcom G7 15 Day CGM
  • Researchers say they can use imaging to measure blood glucose for people with diabetes
  • Dexcom launches program to enhance healthcare provider CGM knowledge
  • Insulet wins FDA clearance for Omnipod 5 algorithm enhancements
  • FDA accepts MannKind sNDA for autoinjector that treats edema

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS